<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343863</url>
  </required_header>
  <id_info>
    <org_study_id>6140</org_study_id>
    <secondary_id>NCI-2010-00801</secondary_id>
    <nct_id>NCT00343863</nct_id>
  </id_info>
  <brief_title>Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer</brief_title>
  <official_title>Efficacy of Palonosetron in the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Following Dose Dense Adriamycin-Cyclophosphamide Chemotherapy in Early Stage Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and
      palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by
      chemotherapy.

      PURPOSE: This clinical trial studies how well giving dexamethasone together with ondansetron
      hydrochloride or palonosetron hydrochloride works in preventing nausea and vomiting in
      patients receiving doxorubicin hydrochloride and cyclophosphamide for early stage breast
      cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the proportion of patients achieving a complete response (CR), defined as no
      emesis and no rescue medications in the 0-24 hour time period following weekly intravenous
      doxorubicin.

      SECONDARY OBJECTIVES:

      I. To determine the proportion of patients achieving a complete response (CR), defined as no
      emesis and no rescue medications in the 24-120 hour time period following weekly intravenous
      doxorubicin.

      II. To determine the proportion of patients achieving a complete response (CR), defined as no
      emesis and no rescue medications in the 0-120 hour time period following weekly intravenous
      doxorubicin.

      III. To determine the number of emetic episodes daily and cumulatively for the 24-120, and
      0-120 hour time periods.

      IV. To determine the time to first emetic episode. V. To determine the time to first
      administration of rescue medication. VI. To determine the time to treatment failure (time to
      first emetic episode or administration of rescue medication, whichever occurred first).

      VII. To determine the number of doses of rescue medications used. VIII. To determine the side
      effects of antiemetic medications used. IX. To determine theseverity of nausea. X. To
      evaluate quality of life.

      OUTLINE: Patients are assigned to 1 of 2 treatment groups.

      All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days
      1-7.

      GROUP I: Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to
      each dose of doxorubicin hydrochloride).

      GROUP II: Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to
      each dose of doxorubicin hydrochloride).

      Treatment repeats every 7 days for 12-15 courses in the absence of disease progression or
      unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of Patients Achieving a Complete Response</measure>
    <time_frame>At 0-24 hours after weekly intravenous doxorubin</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Count of Patients Achieving Complete Response</measure>
    <time_frame>At 24-120 hours after weekly intravenous doxorubicin</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Emetic Episodes and Rescue Medicines</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Had Emesis Within 48 Hours of Chemotherapy</measure>
    <time_frame>Up to 48 hours of chemotherapy</time_frame>
    <description>Count of patients that had emesis within 48 hours of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Had First Administration of Rescue Medication Within 48 Hours</measure>
    <time_frame>up to 48 hours of chemotherapy</time_frame>
    <description>Count of patients that had first administration of rescue medication within 48 Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Doses of Rescue Medications Used</measure>
    <time_frame>Days 1-7 of each cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects of Antiemetic Medications Used</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Nausea</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Count of participants with severe nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Male Breast Cancer</condition>
  <condition>Nausea and Vomiting</condition>
  <condition>Stage I Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dexamethasone + Ondansetron IV on Day 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone + Palonosetron IV on Day 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palonosetron hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Dexamethasone + Palonosetron IV on Day 1</arm_group_label>
    <other_name>Aloxi</other_name>
    <other_name>RS 25259-197</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Dexamethasone + Ondansetron IV on Day 1</arm_group_label>
    <arm_group_label>Dexamethasone + Palonosetron IV on Day 1</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given orally or IV</description>
    <arm_group_label>Dexamethasone + Ondansetron IV on Day 1</arm_group_label>
    <arm_group_label>Dexamethasone + Palonosetron IV on Day 1</arm_group_label>
    <other_name>Aeroseb-Dex</other_name>
    <other_name>Decaderm</other_name>
    <other_name>Decadron</other_name>
    <other_name>DM</other_name>
    <other_name>DXM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Dexamethasone + Ondansetron IV on Day 1</arm_group_label>
    <arm_group_label>Dexamethasone + Palonosetron IV on Day 1</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Dexamethasone + Ondansetron IV on Day 1</arm_group_label>
    <arm_group_label>Dexamethasone + Palonosetron IV on Day 1</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nausea and vomiting therapy</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Dexamethasone + Ondansetron IV on Day 1</arm_group_label>
    <arm_group_label>Dexamethasone + Palonosetron IV on Day 1</arm_group_label>
    <other_name>antiemetic support</other_name>
    <other_name>management of nausea and vomiting</other_name>
    <other_name>nausea and vomiting management</other_name>
    <other_name>therapy, nausea and vomiting</other_name>
    <other_name>vomiting and nausea management</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>management of therapy complications</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Dexamethasone + Ondansetron IV on Day 1</arm_group_label>
    <arm_group_label>Dexamethasone + Palonosetron IV on Day 1</arm_group_label>
    <other_name>complications of therapy, management of</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Dexamethasone + Ondansetron IV on Day 1</arm_group_label>
    <other_name>GR 38032F</other_name>
    <other_name>GR-C507/75</other_name>
    <other_name>SN-307</other_name>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>survey administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Dexamethasone + Ondansetron IV on Day 1</arm_group_label>
    <arm_group_label>Dexamethasone + Palonosetron IV on Day 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a histologically confirmed diagnosis of primary breast carcinoma

          -  Patient must be naive to chemotherapy at the time of enrollment

          -  Patients must have prescribed weekly intravenous adriamycin (doxorubicin) and daily
             oral cyclophosphamide treatment for early breast cancer

          -  The patient must be informed of the investigational nature of this study and must sign
             and give written informed consent in accordance with institutional and federal
             guidelines

          -  Patients must have a Karnofsky index of greater than or equal to 50%

          -  Known mild to moderate hepatic, renal or cardiovascular impairment may be enrolled at
             the discretion of the investigator

        Exclusion Criteria:

          -  Receipt of investigational drug within 30 days before study entry

          -  Received any drug with potential anti-emetic effect within 24 hours prior to the start
             of study-designated chemotherapeutic agent (with the exception of administration of
             the palonosetron/dexamethasone infusion solution), including the following: 5-HT3
             receptor antagonists; dopamine receptor antagonists (metoclopramide); phenothiazine
             anti-emetics (prochlorperazine, thiethylperazine and perphenazine); diphenhydramine,
             scopolamine, chlorpheniramine maleate, trimethobenzamide (diphenhydramine will be
             allowed if given for prophylactic treatment of hypersensitivity reactions associated
             with the administration of Taxanes); all benzodiazepines; haloperidol, droperidol,
             tetrahydrocannabinol, or nabilone; any systemic corticosteroid (hydrocortisone,
             methylprednisolone, prednisone) (topical or inhaled preparations are allowed)

          -  Any vomiting, retching or NCI Common Toxicity Criteria version 3.0 grade 2-4 nausea in
             the 24 hours preceding chemotherapy

          -  Ongoing vomiting from any organic etiology

          -  Need to receive systemic corticosteroids, except: a) when defined as part of the
             chemotherapy regimen as a preventative measure for chemotherapy toxicities; b) topical
             or inhaled preparations; and/or c) when used as rescue medication during the study

          -  Known contraindication to 5-HT3 receptor antagonists (including palonosetron) or
             dexamethasone

          -  Need to receive radiotherapy during the study

          -  Inability to understand or cooperate with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannah Linden</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2006</study_first_submitted>
  <study_first_submitted_qc>June 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2006</study_first_posted>
  <results_first_submitted>April 14, 2017</results_first_submitted>
  <results_first_submitted_qc>June 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 11, 2017</results_first_posted>
  <last_update_submitted>June 10, 2017</last_update_submitted>
  <last_update_submitted_qc>June 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Hannah Linden</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone + Ondansetron IV</title>
          <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
        </group>
        <group group_id="P2">
          <title>Dexamethasone + Palonosetron IV</title>
          <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone + Ondansetron IV</title>
          <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
        </group>
        <group group_id="B2">
          <title>Dexamethasone + Palonosetron IV</title>
          <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="45" upper_limit="63"/>
                    <measurement group_id="B2" value="49" lower_limit="29" upper_limit="69"/>
                    <measurement group_id="B3" value="50" lower_limit="29" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Count of Patients Achieving a Complete Response</title>
        <time_frame>At 0-24 hours after weekly intravenous doxorubin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone + Ondansetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone + Palonosetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Patients Achieving a Complete Response</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Patients Achieving Complete Response</title>
        <time_frame>At 24-120 hours after weekly intravenous doxorubicin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone + Ondansetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone + Palonosetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Patients Achieving Complete Response</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Emetic Episodes and Rescue Medicines</title>
        <time_frame>Up to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone + Ondansetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone + Palonosetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Emetic Episodes and Rescue Medicines</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vomiting during neoadjuvant chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="51"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Took rescue medicines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="70"/>
                    <measurement group_id="O2" value="9.5" lower_limit="0" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Had Emesis Within 48 Hours of Chemotherapy</title>
        <description>Count of patients that had emesis within 48 hours of chemotherapy</description>
        <time_frame>Up to 48 hours of chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone + Ondansetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone + Palonosetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Had Emesis Within 48 Hours of Chemotherapy</title>
          <description>Count of patients that had emesis within 48 hours of chemotherapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Had First Administration of Rescue Medication Within 48 Hours</title>
        <description>Count of patients that had first administration of rescue medication within 48 Hours</description>
        <time_frame>up to 48 hours of chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone + Ondansetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone + Palonosetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Had First Administration of Rescue Medication Within 48 Hours</title>
          <description>Count of patients that had first administration of rescue medication within 48 Hours</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Doses of Rescue Medications Used</title>
        <time_frame>Days 1-7 of each cycle</time_frame>
        <population>Patients were unable to consistently complete this part of the FLIE questionnaire and thus we did not retain data from any of the participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone + Ondansetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone + Palonosetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Doses of Rescue Medications Used</title>
          <population>Patients were unable to consistently complete this part of the FLIE questionnaire and thus we did not retain data from any of the participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects of Antiemetic Medications Used</title>
        <time_frame>Up to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone + Ondansetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone + Palonosetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects of Antiemetic Medications Used</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headaches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Nausea</title>
        <description>Count of participants with severe nausea</description>
        <time_frame>Up to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone + Ondansetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone + Palonosetron IV</title>
            <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Nausea</title>
          <description>Count of participants with severe nausea</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <time_frame>Up to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone + Ondansetron IV</title>
            <description>Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone + Palonosetron IV</title>
            <description>Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <units>FLIE questionnaires</units>
          <param>Count of Units</param>
          <units_analyzed>FLIE questionnaires</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>FLIE questionnaires</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FLIE Nausea</title>
              <category_list>
                <category>
                  <title>High impact (&lt;36)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Medium impact (36-54)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No impact of daily life (&gt;54)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLIE Vomiting</title>
              <category_list>
                <category>
                  <title>High impact (&lt;36)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Medium impact (36-54)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No impact of daily life (&gt;54)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone + Ondansetron IV</title>
          <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
        </group>
        <group group_id="E2">
          <title>Dexamethasone + Palonosetron IV</title>
          <description>All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hannah Linden</name_or_title>
      <organization>University of Washington / Seattle Cancer Care Alliance</organization>
      <phone>206-288-6989</phone>
      <email>hmlinden@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

